Observational studyBMC pediatrics2026
Antimicrobial use in pediatric hematopoietic stem cell transplantation in China: a retrospective multicenter cohort study.
Observational study in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHematopoietic stem cell transplantation (HSCT) is integral to the management of pediatric hematologic malignancies and non-malignant disease, but infection is a significant cause of morbidity and mortality. The purpose of this study is to assess the application of antimicrobial agents in pediatric HSCT.
methodsThis multicenter retrospective observational cohort study was conducted across 21 hospitals in China. We included pediatric patients who underwent HSCT and received antimicrobial treatment between January 2023 and April 2024. The study collected and analyzed data on patients' disease types, antibiotic use, antifungal drug use, and treatment durations, with subgroup analysis based on age. Statistical analysis was performed using Python 3.13.
resultsWe included a total of 186 patients with 73 patients in the tumor group and 113 patients in the non-tumor group. The most frequent disease in the tumor group was acute lymphoblastic leukemia (37 patients, 50.68%), and the most frequent disease in the non-tumor group was mucopolysaccharidosis (48 patients, 42.48%). The antibiotic piperacillin-tazobactam (136 prescriptions, 63.85%) and antifungal agents fluconazole (118 prescriptions) and voriconazole (72 prescriptions, 36.36%) were the most frequently applied antibiotics and antifungal agents, respectively. In patients receiving antibacterial therapy, the median treatment period was 10 days, and the majority of patients were found to have treatment periods of between 7 and 14 days. This corresponded to a non-significant trend toward longer treatment in school-age children compared with infants (10 vs. 8 days).
conclusionIn pediatric HSCT recipients, antibacterial and antifungal therapy is predominantly broad-spectrum with moderate durations; school-age children have slightly longer courses without significant differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.